Pure Global

QIAstat-Dx ME Panel - India CDSCO Medical Device Registration

QIAstat-Dx ME Panel is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID IMP/IVD/2023/000190_a1e0c8b95e25f57de9e0cb0c514b1633_30601224158fd778d58cfd1d8a27c787. This device is marketed under the brand name QIAstat-Dx. The license holder is QIAGEN India Pvt. Ltd, and it is classified as Device Class Class C. The approving authority is CDSCO.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
CDSCO Registered
Class Class C
QIAstat-Dx ME Panel
UID: IMP/IVD/2023/000190_a1e0c8b95e25f57de9e0cb0c514b1633_30601224158fd778d58cfd1d8a27c787

Brand Name

QIAstat-Dx

License Holder

QIAGEN India Pvt. Ltd

Device Class

Class C

Approving Authority

CDSCO

Product Information

The QIAstat-Dx Meningitis/Encephalitis (QIAstat-Dx) Panel (QIAstat-Dx) is a qualitative multiplexed nucleic acid-based in vitro diagnostic test intended for use with the QIAstat-Dx System. The QIAstat-Dx ME Panel is capable of simultaneous detection and identification of multiple bacterial, viral, and yeast nucleic acids from cerebrospinal fluid (QIAstat-Dx) specimens obtained via lumbar puncture from individuals with signs and/or symptoms of meningitis and/or encephalitis. The following organisms are identified and differentiated using the QIAstat-Dx ME Panel: Escherichia coli K1, Haemophilus influenzae, Listeria monocytogenes, Neisseria meningitidis (QIAstat-Dx), Streptococcus agalactiae, Streptococcus pneumoniae, Mycoplasma pneumoniae, Streptococcus pyogenes, Herpes simplex virus 1, Herpes simplex virus 2, Human herpes virus 6, Enterovirus, Human parechovirus, Varicella-zoster virus and Cryptococcus neoformans/gattii*. The QIAstat-Dx ME Panel is indicated as an aid in the diagnosis of specific agents of meningitis and/or encephalitis and results must be used in conjunction with other clinical, epidemiological, and laboratory data. Results from the QIAstat-Dx ME Panel are not intended to be used as the sole basis for diagnosis, treatment, or other patient management decisions. Positive results do not rule out co-infection with organisms not included in the QIAstat-Dx ME Panel. The agent or agents detected may not be the definite cause of the disease. Negative results do not preclude central nervous system (QIAstat-Dx) infection. Not all agents of CNS infection are detected by this test, and sensitivity in clinical use may differ from that described in the package insert.

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing